Antares Pharma Inc  

(Public, NASDAQ:ATRS)   Watch this stock  
Find more results for ATRS
1.00
-0.01 (-0.99%)
After Hours: 1.04 +0.04 (4.00%)
Jul 27, 4:01PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.00 - 1.02
52 week 0.67 - 2.25
Open 1.01
Vol / Avg. 218,755.00/1.21M
Mkt cap 156.48M
P/E     -
Div/yield     -
EPS -0.14
Shares 154.93M
Beta 0.70
Inst. own 43%
Aug 8, 2016
Q2 2016 Antares Pharma Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 8, 2016
Antares Pharma Inc at Jefferies Healthcare Conference - Webcast
Jun 2, 2016
Antares Pharma Inc Annual Shareholders Meeting
May 27, 2016
Antares Pharma Inc Annual Shareholders Meeting (Estimated)
May 9, 2016
Q1 2016 Antares Pharma Inc Earnings Release
May 9, 2016
Q1 2016 Antares Pharma Inc Earnings Call
May 4, 2016
Antares Pharma Inc at Deutsche Bank Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -62.15% -45.25%
Operating margin -62.57% -44.82%
EBITD margin - -41.38%
Return on average assets -37.03% -26.95%
Return on average equity -48.39% -38.17%
Employees 108 -
CDP Score - -

Address

SUITE 300, 100 PRINCETON SOUTH
EWING, NJ 8628
United States - Map
+1-609-3593020 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company makes a reusable, needle-free spring action injection device, ZOMA-Jet or Twin-Jector, which is marketed through its partners for use with human growth hormone (hGH). The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.

Officers and directors

Leonard S. Jacob M.D., Ph.D. Independent Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Robert F. Apple CPA President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
James E. Fickenscher Chief Financial Officer, Senior Vice President
Age: 51
Bio & Compensation  - Reuters
Peter J. Graham Esq. Senior Vice President, General Counsel, Human Resources, Chief Compliance Officer
Age: 48
Bio & Compensation  - Reuters
Thomas J. Garrity Independent Director
Age: 66
Bio & Compensation  - Reuters
Jacques Gonella Ph.D. Independent Director
Age: 73
Bio & Compensation  - Reuters
Anton G. Gueth Independent Director
Age: 58
Bio & Compensation  - Reuters
Robert P. Roche Jr. Independent Director
Age: 59
Bio & Compensation  - Reuters
Marvin S. Samson Independent Director
Age: 74
Bio & Compensation  - Reuters